Stereochemistry | ABSOLUTE |
Molecular Formula | C20H34O5 |
Molecular Weight | 354.481 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
InChI
InChIKey=PXGPLTODNUVGFL-YNNPMVKQSA-N
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1
Molecular Formula | C20H34O5 |
Molecular Weight | 354.481 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 2 |
Optical Activity | UNSPECIFIED |
Dinoprost is the synthetic or partially synthetic, naturally-occurring prostaglandin F2 alpha (trade mark Prostin F2 alpha). Dinoprost has been used for therapeutic termination of pregnancy. Although the exact mode of action in pregnancy termination in humans is not fully defined, when Prostin F2 alpha is administered by the intrauterine route it initiates rhythmical uterine contractions which, if continued for a sufficient time, are capable of expelling the contents of
the uterus. Sensitivity of the pregnant uterus to prostaglandins is lower during early and mid-pregnancy than at term.
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
For Extra-amniotic Route
A solution containing 250 μg/mL Prostin F2 alpha should be prepared. Insert a 12 to 14
French gauge Foley catheter with self-retaining 30 mL balloon through the cervix into the
space between the fetal membranes and the uterine wall (extra-ovular or extra-amniotic), so
that the balloon passes just beyond the internal os. Fill the balloon with 30 mL sterile water
(a fine polyethylene catheter has also been used). The Prostin F2 alpha solution should then
be instilled through the catheter.
After filling the catheter system deadspace with a predetermined quantity of dilute solution,
the initial dose should be 1 mL. Subsequent instillations should be 3 mL, unless side effects
ensue, when the dose may be reduced to 1 or 2 mL or the interval between doses prolonged.
Two hours should usually elapse between each installation and never less than 1 hour.
For Intra-amniotic Route
A transabdominal tap of the amniotic sac should be accomplished with an appropriate sized
needle and at least 1 mL of amniotic fluid should be withdrawn, then 40 mg (8 mL) of Prostin
F2 alpha is slowly injected into the amniotic sac. It is suggested that the first millilitre be
injected very slowly to determine possible sensitivity prior to completing the total 40 mg
dose. Do not inject medication in the case of a bloody tap.
If within 24 hours of the initial dose the abortion process has not been established or completed
(and in the presence of intact membranes), an additional 10-40 mg (2-8 mL) of Prostin F2 alpha
may be administered.
Route of Administration:
Other
Bobine luteal cells obtained at the mid-luteal stage (days 8-12 after ovulation) were cultured with prostaglandin F2α (PGF) (0.01, 0.1, 1 μM), interferon γ (IFNG) (0.05, 0.5, 5 nM) and tumor necrosis factor α (TNF) (0.05, 0.5, 0.5 nM) alone or in combination for 24 h. PGF and IFNG significantly increased the expression of MMP-1 mRNA. In addition, 1 μM PGF in combination with 5 nM IFNG stimulated MMP-1 and MMP-9 mRNA expression significantly more than either treatment alone. In contrast, IFNG significantly decreased the level of MMP-14 mRNA. The mRNA expression of TIMP-1, which preferentially inhibits MMP-1, was suppressed by 5 nM INFG. One μM PGF and 5 nM IFNG suppressed TIMP-2 mRNA expression.